2020
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy.
Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: e17575-e17575. DOI: 10.1200/jco.2020.38.15_suppl.e17575.Peer-Reviewed Original ResearchTime to progressionMedian time to PSA progressionSequencing of therapeutic agentsTime to PSA progressionTime-to-progression analysisPSA response rateTreatment of mCRPCMinimize treatment toxicityPrevent drug resistanceLong-term suppressionObservations of efficacyPSA progressionMedian followRestarting therapyAntitumor benefitRadium-223Study regimenTreatment toxicityStudy regimensPrimary endpointProstate cancerMCRPCTherapy completionDrug resistanceRegimenPRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy.
Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.6_suppl.89.Peer-Reviewed Original ResearchTime to progressionMedian time to PSA progressionSequencing of therapeutic agentsTime to PSA progressionTime-to-progression analysisPSA response rateTreatment of mCRPCLong-term suppressionObservations of efficacyPSA progressionMedian followRestarting therapyAntitumor benefitRadium-223Study regimenStudy regimensPrimary endpointProstate cancerMCRPCTherapy completionDrug resistanceRegimenDrug selectionDelay progressionPatients
2019
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy.
Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy. Journal Of Clinical Oncology 2019, 37: 310-310. DOI: 10.1200/jco.2019.37.7_suppl.310.Peer-Reviewed Original ResearchPrimary endpointMedian time to PSA progressionTime to PSA progressionTime to disease progressionPSA response rateTreatment of mCRPCMinimize treatment toxicityPrevent drug resistancePSA progressionMedian followAntitumor benefitMonthly regimenRadium-223Bone metastasesTreatment toxicityStudy regimensProstate cancerMCRPCHeterogeneous diseaseDrug resistanceDisease progressionWeeks durationDelay progressionResponse ratePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply